🚀 VC round data is live in beta, check it out!
Sichuan Biokin Overview
About Sichuan Biokin
Sichuan Biokin Pharmaceutical Co Ltd is a chemical drug and biological drug-based company that integrates drug research and development, production and marketing.
Founded
2006
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$18B
Sichuan Biokin Financials
Sichuan Biokin reported last 12-month revenue of $338M and negative EBITDA of ($38M).
In the same LTM period, Sichuan Biokin generated $306M in gross profit, ($38M) in EBITDA losses, and had net loss of ($109M).
Revenue (LTM)
Sichuan Biokin P&L
In the most recent fiscal year, Sichuan Biokin reported revenue of $854M and EBITDA of $601M.
Sichuan Biokin expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $338M | XXX | $854M | XXX | XXX | XXX |
| Gross Profit | $306M | XXX | $815M | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | 95% | XXX | XXX | XXX |
| EBITDA | ($38M) | XXX | $601M | XXX | XXX | XXX |
| EBITDA Margin | (11%) | XXX | 70% | XXX | XXX | XXX |
| EBIT Margin | (20%) | XXX | 64% | XXX | XXX | XXX |
| Net Profit | ($109M) | XXX | $544M | XXX | XXX | XXX |
| Net Margin | (32%) | XXX | 64% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sichuan Biokin Stock Performance
Sichuan Biokin has current market cap of $18B, and enterprise value of $18B.
Market Cap Evolution
Sichuan Biokin's stock price is $43.75.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $18B | $18B | -4.6% | XXX | XXX | XXX | $1.32 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSichuan Biokin Valuation Multiples
Sichuan Biokin trades at 52.4x EV/Revenue multiple, and (466.9x) EV/EBITDA.
EV / Revenue (LTM)
Sichuan Biokin Financial Valuation Multiples
As of April 18, 2026, Sichuan Biokin has market cap of $18B and EV of $18B.
Equity research analysts estimate Sichuan Biokin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sichuan Biokin has a P/E ratio of (165.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $18B | XXX | $18B | XXX | XXX | XXX |
| EV (current) | $18B | XXX | $18B | XXX | XXX | XXX |
| EV/Revenue | 52.4x | XXX | 20.7x | XXX | XXX | XXX |
| EV/EBITDA | (466.9x) | XXX | 29.5x | XXX | XXX | XXX |
| EV/EBIT | (260.9x) | XXX | 32.3x | XXX | XXX | XXX |
| EV/Gross Profit | 57.9x | XXX | 21.7x | XXX | XXX | XXX |
| P/E | (165.9x) | XXX | 33.2x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 30.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sichuan Biokin Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sichuan Biokin Margins & Growth Rates
Sichuan Biokin's revenue in the last 12 month grew by 23%.
Sichuan Biokin's rule of 40 is 1% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sichuan Biokin's rule of X is 18% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Sichuan Biokin Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | (62%) | XXX | XXX | XXX |
| EBITDA Margin | (11%) | XXX | 70% | XXX | XXX | XXX |
| EBITDA Growth | (28%) | XXX | (106%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 1% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 18% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 9% | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 11% | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 97% | XXX | 25% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sichuan Biokin Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
Valuation data powered by FactSet, Inc.
Sichuan Biokin M&A Activity
Sichuan Biokin acquired XXX companies to date.
Last acquisition by Sichuan Biokin was on XXXXXXXX, XXXXX. Sichuan Biokin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sichuan Biokin
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSichuan Biokin Investment Activity
Sichuan Biokin invested in XXX companies to date.
Sichuan Biokin made its latest investment on XXXXXXXX, XXXXX. Sichuan Biokin invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sichuan Biokin
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sichuan Biokin
| When was Sichuan Biokin founded? | Sichuan Biokin was founded in 2006. |
| Where is Sichuan Biokin headquartered? | Sichuan Biokin is headquartered in China. |
| Is Sichuan Biokin publicly listed? | Yes, Sichuan Biokin is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Sichuan Biokin? | Sichuan Biokin trades under 688506 ticker. |
| When did Sichuan Biokin go public? | Sichuan Biokin went public in 2023. |
| Who are competitors of Sichuan Biokin? | Sichuan Biokin main competitors are Akeso, Genmab, Shionogi, Viatris. |
| What is the current market cap of Sichuan Biokin? | Sichuan Biokin's current market cap is $18B. |
| What is the current revenue of Sichuan Biokin? | Sichuan Biokin's last 12 months revenue is $338M. |
| What is the current revenue growth of Sichuan Biokin? | Sichuan Biokin revenue growth (NTM/LTM) is 23%. |
| What is the current EV/Revenue multiple of Sichuan Biokin? | Current revenue multiple of Sichuan Biokin is 52.4x. |
| Is Sichuan Biokin profitable? | No, Sichuan Biokin is not profitable. |
| What is the current EBITDA of Sichuan Biokin? | Sichuan Biokin has negative EBITDA and is not profitable. |
| What is Sichuan Biokin's EBITDA margin? | Sichuan Biokin's last 12 months EBITDA margin is (11%). |
| What is the current EV/EBITDA multiple of Sichuan Biokin? | Current EBITDA multiple of Sichuan Biokin is (466.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.